A multicentre randomised controlled, open-label, pragmatic clinical trial, with internal pilot phase, designed to test both the clinical and cost effectiveness of AOT in patients with IPF.

The primary aim of OXYPuF is to assess the clinical and cost effectivenss of ambulatory oxygen therapy in patients with idiopathic pulmonary fibrosis.

Suitable patients will be identified at NHS Trusts across the country.

260 consenting adults diagnosed with IPF confirmed via a multidisciplinary team (MDT) meeting or an IPF specialist.

Participants will be randomised to receive either AOT and breathlessness advice or breathlessness advice only. 

Primary objective:

To determine whether ambulatory oxygen therapy (AOT) is clinically and cost effective in patients with idiopathic pulmonary fibrosis (IPF).

Secondary objectives:

•Determine whether breathlessness, determined by sub-scales of the King’s Brief Interstitial Lung Disease (K-BILD) is superior after AOT compared to standardised breathlessness advice at 6 months.

• Determine whether MRC dyspnoea score, is superior after AOT compared to standardised breathlessness advice at 6 months.

• Determine whether exercise capacity and physical activity, as measured by the six minute walk test (6MWT) or a sit to stand test (depending on local policy), and a self-reported activity questionnaire (International Physical Activity Questionnaire; IPAQ) respectively, is superior after AOT compared to standardised breathlessness advice at 6 months.

For further information please contact the trials office.